سعر سكيفالورين 2.5مجم/5مل شراب 150 مل 2026

Skivalorine syrup: desloratadine 2.5 mg/5 ml oral syrup, 150 ml bottle, by Sonesta Pharma (Egypt); second-generation antihistamine.

• Seasonal allergic rhinitis: relief of nasal and non-nasal symptomsPopulation: 2 years and olderDailyMed (U.S. National Library of Medicine)
• Perennial allergic rhinitis: relief of nasal and non-nasal symptomsPopulation: 6 months and olderDailyMed (U.S. National Library of Medicine)
• Chronic idiopathic urticaria: relief of pruritus and reduction in number and size of hivesPopulation: 6 months and olderDailyMed (U.S. National Library of Medicine)

• In placebo-controlled trials of the oral solution in children aged 6 months to 11 years, no individual adverse event was reported by 2% or more of subjects aged 6-11 years; in adults and adolescents, common events included pharyngitis, dry mouth, myalgia, fatigue, somnolence and dysmenorrhoea.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Post-marketing reports include tachycardia, palpitations, psychomotor hyperactivity, seizures, elevated liver enzymes, hepatitis and hypersensitivity reactions.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to desloratadine, to any of its ingredients, or to loratadine.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity reactions including rash, pruritus, urticaria, oedema, dyspnoea and anaphylaxis have been reported; stop treatment at once and consider alternatives.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Ketoconazole, erythromycin, azithromycin (CYP3A4 inhibitors)Co-administration increased plasma concentrations of desloratadine and 3-hydroxydesloratadine, with no clinically relevant change in the safety profile.DailyMed (U.S. National Library of Medicine)
• FluoxetineCo-administration increased desloratadine and 3-hydroxydesloratadine concentrations, with no clinically relevant change in the safety profile.DailyMed (U.S. National Library of Medicine)
• CimetidineCo-administration increased desloratadine and 3-hydroxydesloratadine concentrations, with no clinically relevant change in the safety profile.DailyMed (U.S. National Library of Medicine)

• Limited human data are insufficient to inform a drug-associated risk of major birth defects or miscarriage; desloratadine was not teratogenic in rats or rabbits at exposures far above human exposure.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Desloratadine passes into breast milk; weigh the benefits of breastfeeding, the mother's clinical need and possible effects on the infant when deciding whether to continue.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Desloratadine: Long-acting histamine antagonist with selective peripheral H1-receptor antagonist activity.